Development of anti-HER2 monoclonal antibodies for gastric cancer

被引：0
|
作者：
Nanamiya, Ren [1 ]
Suzuki, Hiroyuki [2 ]
Kato, Yukinari [1 ,2 ]
机构：
[1] Tohoku Univ, Dept Antibody Drug Dev, Grad Sch Med, Sendai, Miyagi, Japan
[2] Tohoku Univ, Dept Mol Pharmacol, Grad Sch Med, Sendai, Miyagi, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1164
引用
收藏
页码：589 / 589
页数：1
相关论文
共 50 条
  • [1] Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
    Yu, Shengnan
    Liu, Qian
    Han, Xinwei
    Qin, Shuang
    Zhao, Weiheng
    Li, Anping
    Wu, Kongming
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
  • [2] Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
    Shengnan Yu
    Qian Liu
    Xinwei Han
    Shuang Qin
    Weiheng Zhao
    Anping Li
    Kongming Wu
    Experimental Hematology & Oncology, 6
  • [3] Production and characterizing anti-Her2 monoclonal antibodies
    Tabatabaei-Panah, A. S.
    Zarnani, A. H.
    Montaser-Kouhsari, Sh.
    Chamankhah, M.
    Ghods, R.
    Bayat, A. A.
    Kazemi-Sefat, G. E.
    Mahmoudi, S. A. R.
    Karampour, M. Ostad
    Shojaeian, S.
    Jeddi-Tehrani, M.
    YAKHTEH, 2008, 10 (02): : 109 - 120
  • [4] Mechanism of action of anti-HER2 monoclonal antibodies
    Baselga, J
    Albanell, J
    ANNALS OF ONCOLOGY, 2001, 12 : 35 - 41
  • [5] Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy
    Gornowicz, Agnieszka
    Szymanowski, Wojciech
    Czarnomysy, Robert
    Bielawski, Krzysztof
    Bielawska, Anna
    PLOS ONE, 2021, 16 (08):
  • [6] Development of competing and non-competing fully human internalizing anti-Her2 monoclonal antibodies
    Serrero, Ginette
    Yue, Binbin
    Dong, Jianping
    Dong, Chun
    Hayashi, Jun
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer
    Musolino, Antonino
    Boggiani, Daniela
    Pellegrino, Benedetta
    Zanoni, Daniele
    Sikokis, Angelica
    Missale, Gabriele
    Silini, Enrico Maria
    Maglietta, Giuseppe
    Frassoldati, Antonio
    Michiara, Maria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 149
  • [8] In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells
    Tahmasebi, Fathollah
    Kazemi, Tohid
    Amiri, Mohammad Mehdi
    Khoshnoodi, Jalal
    Mahmoudian, Jafar
    Bayat, Ali Ahmad
    Jeddi-Tehrani, Mahmood
    Rabbani, Hodjatallah
    Shokri, Fazel
    IMMUNOTHERAPY, 2014, 6 (01) : 43 - 49
  • [9] Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody
    Amiri, Mohammad Mehdi
    Bahadori, Tannaz
    Soltantoyeh, Tahereh
    Hosseini-Ghatar, Reza
    Golsaz-Shirazi, Forough
    Jeddi-Tehrani, Mahmood
    Shokri, Fazel
    IRANIAN JOURNAL OF IMMUNOLOGY, 2019, 16 (01) : 26 - 42
  • [10] Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
    Vazquez-Martin, Alejandro
    Oliveras-Ferraros, Cristina
    Menendez, Javier A.
    PLOS ONE, 2009, 4 (07):
12345